NOVAREX Co.,Ltd. (KOSDAQ:194700)
13,610
+210 (1.57%)
At close: Apr 9, 2026
NOVAREX Revenue
In the year 2025, NOVAREX had annual revenue of 404.26B KRW with 35.78% growth. NOVAREX had revenue of 100.65B in the quarter ending December 31, 2025, with 22.52% growth.
Revenue
404.26B
Revenue Growth
+35.78%
P/S Ratio
0.61
Revenue / Employee
871.25M
Employees
464
Market Cap
247.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 404.26B | 106.53B | 35.78% |
| Dec 31, 2024 | 297.73B | -4.44B | -1.47% |
| Dec 31, 2023 | 302.17B | 20.49B | 7.28% |
| Dec 31, 2022 | 281.68B | 2.89B | 1.04% |
| Dec 31, 2021 | 278.79B | 55.96B | 25.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DongKoo Bio & Pharma | 242.69B |
| Kyung Dong Pharmaceutical | 196.27B |
| GREEN CROSS WellBeing | 164.68B |
| DAE HWA Pharmaceutical | 143.06B |
| OPTUS Pharmaceutical | 87.16B |
| High Tech Pharm | 70.18B |
| Vivozon Pharmaceutical | 59.34B |
| HEM Pharma | 12.98B |